InfuSystem Holdings Inc (INFU)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$12.24+0.49%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · INFU
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $12 INFU trades at 27× p/e, below its 28× p/e peer median, but our blended $11 fair value sits below the price. It's a high-confidence read. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $13.29 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $13.34 | — | — | Hist. CAGR | high |
| graham number | 12M | $5.35 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $7.84 | 6.2 | 1.26 | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.11/sh owner earnings.
Roughly priced in line with peers.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $18.75 |
| 24.6 |
| 0.76 |
| TTM |
| high |
| Peer P/E | 12M | $12.72 | 28.3 | 0.45 | TTM | high |
| Peer P/S | 12M | $20.17 | 2.9 | 6.85 | TTM | high |
| residual income | 12M | $3.75 | — | — | TTM | high |
| Own P/E history | 12M | $10.99 | 24.4 | 0.45 | TTM | high |
| triangulated | 12M | $13.84 | 28.3 | 0.49 | Triangulated | high |
| Peer P/S | 3Y | $24.26 | 2.9 | 8.24 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $27.59 | 2.9 | 9.37 | Hist. CAGR(prov.) | medium |